Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peptic Ulcers – Pipeline Review, H2 2016, provides an overview of the Peptic Ulcers (Gastrointestinal) pipeline landscape.
Peptic ulcers are open sores that develop on the inside lining of esophagus, stomach and the upper portion of small intestine. Symptoms include nausea or vomiting, unexplained weight loss, appetite changes and abdominal pain. Risk factors include smoking and alcoholism. Treatment includes antibiotic, acid blockers, antacids and proton pump inhibitors.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peptic Ulcers – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Peptic Ulcers (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Peptic Ulcers (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Peptic Ulcers and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 2, 3 and 11 respectively.
Peptic Ulcers (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Peptic Ulcers (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Peptic Ulcers (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Peptic Ulcers (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Peptic Ulcers (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Peptic Ulcers (Gastrointestinal)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Peptic Ulcers (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Peptic Ulcers (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
Astellas Pharma Inc
Boryung Pharmaceutical Co Ltd
ChoDang Pharm Co Ltd
Daewoong Pharmaceutical Co Ltd
Kukje Pharmaceutical Industry Co Ltd
RaQualia Pharma Inc
Sequella Inc
Sinil Pharmaceutical Co Ltd
XuanZhu Pharma Co Ltd
Yooyoung Pharmaceutical Co Ltd
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Peptic Ulcers Overview 7
Therapeutics Development 8
Pipeline Products for Peptic Ulcers - Overview 8
Peptic Ulcers - Therapeutics under Development by Companies 9
Peptic Ulcers - Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Peptic Ulcers - Products under Development by Companies 12
Peptic Ulcers - Companies Involved in Therapeutics Development 13
Astellas Pharma Inc 13
Boryung Pharmaceutical Co Ltd 14
ChoDang Pharm Co Ltd 15
Daewoong Pharmaceutical Co Ltd 16
Kukje Pharmaceutical Industry Co Ltd 17
RaQualia Pharma Inc 18
Sequella Inc 19
Sinil Pharmaceutical Co Ltd 20
XuanZhu Pharma Co Ltd 21
Yooyoung Pharmaceutical Co Ltd 22
Peptic Ulcers - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Combination Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 30
Drug Profiles 31
(ecabet + ranitidine) - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
(lansoprazole + omeprazole) - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
anaprazole sodium - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
ASP-6537 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
BGC-001 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
cholesteryl glucoside - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
DWJ-1386 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
DWJ-206 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
KJ-14001 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
PMKS-005 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
RQ-00000774 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
SI-001002 SR - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Small Molecule to Inhibit Potassium Transporting ATPase Alpha Chain 1 Inhibitor for Peptic Ulcers and Reflux Esophagitis - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
Small Molecules for Gastric Ulcers - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
SQ-109 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
YYD-601 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
Peptic Ulcers - Dormant Projects 49
Peptic Ulcers - Discontinued Products 51
Peptic Ulcers - Product Development Milestones 52
Featured News & Press Releases 52
Jul 17, 2013: Sihuan Pharmaceutical Secures SFDA Approval for Anaprazole Sodium Category 1.1 New Drug Clinical Studies 52
Dec 06, 2010: Sequella Wins FDA Approval To Begin Phase II Trial Of SQ109 In Helicobacter pylori-Associated Duodenal Ulcers 53
Mar 01, 2010: AstraZeneca Provides An Update On The Status Of Its Arrangements With Merck 53
Jan 07, 2010: AstraZeneca Reaches Agreements With Teva Pharmaceuticals Regarding Nexium And Prilosec US Patent Litigations 54
Apr 15, 2008: AstraZeneca Settles US Nexium Patent Litigation with Ranbaxy 54
Feb 28, 2008: AstraZeneca Provides An Update on the Status of its Arrangements With Merck & Co., Inc. 55
Dec 10, 2007: FDA Concludes There Is No Increased Risk Of Cardiac Events For Patients Treated With Omeprazole And NEXIUM (Esomeprazole Magnesium) 55
Jun 01, 2007: AstraZeneca’s Prilosec Patents Upheld By Court 56
Dec 12, 2003: Astrazeneca Prilosec Patents Upheld by Federal Appeals Court 56
Appendix 57
Methodology 57
Coverage 57
Secondary Research 57
Primary Research 57
Expert Panel Validation 57
Contact Us 57
Disclaimer 58
List of Tables
Number of Products under Development for Peptic Ulcers, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Comparative Analysis by Clinical Stage Development, H2 2016 10
Comparative Analysis by Early Stage Development, H2 2016 11
Products under Development by Companies, H2 2016 12
Peptic Ulcers - Pipeline by Astellas Pharma Inc, H2 2016 13
Peptic Ulcers - Pipeline by Boryung Pharmaceutical Co Ltd, H2 2016 14
Peptic Ulcers - Pipeline by ChoDang Pharm Co Ltd, H2 2016 15
Peptic Ulcers - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2016 16
Peptic Ulcers - Pipeline by Kukje Pharmaceutical Industry Co Ltd, H2 2016 17
Peptic Ulcers - Pipeline by RaQualia Pharma Inc, H2 2016 18
Peptic Ulcers - Pipeline by Sequella Inc, H2 2016 19
Peptic Ulcers - Pipeline by Sinil Pharmaceutical Co Ltd, H2 2016 20
Peptic Ulcers - Pipeline by XuanZhu Pharma Co Ltd, H2 2016 21
Peptic Ulcers - Pipeline by Yooyoung Pharmaceutical Co Ltd, H2 2016 22
Assessment by Monotherapy Products, H2 2016 23
Assessment by Combination Products, H2 2016 24
Number of Products by Stage and Target, H2 2016 26
Number of Products by Stage and Mechanism of Action, H2 2016 28
Number of Products by Stage and Route of Administration, H2 2016 29
Number of Products by Stage and Molecule Type, H2 2016 30
Peptic Ulcers - Dormant Projects, H2 2016 49
Peptic Ulcers - Dormant Projects (Contd..1), H2 2016 50
Peptic Ulcers - Discontinued Products, H2 2016 51
List of Figures
Number of Products under Development for Peptic Ulcers, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Comparative Analysis by Clinical Stage Development, H2 2016 10
Assessment by Monotherapy Products, H2 2016 23
Number of Products by Targets, H2 2016 25
Number of Products by Stage and Targets, H2 2016 25
Number of Products by Top 10 Mechanism of Actions, H2 2016 27
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 27
Number of Products by Stage and Routes of Administration, H2 2016 29
Number of Products by Stage and Molecule Types, H2 2016 30
